Depression Medicines | FDA - U.S. Food and Drug Administration
Use the following information to help you talk to your healthcare provider about medicines called antidepressants that can help treat depression. The medicine charts list FDA-approved products...
Depression | FDA - U.S. Food and Drug Administration
Jul 10, 2024 · Depression is one of the most common mental disorders in the United States. Depression does not discriminate, and can affect anyone regardless of age, race, ethnicity, or …
Women and Depression | FDA
Aug 10, 2023 · FDA information on signs of depression, treatment and depression and pregnancy.
FDA clears first digital treatment for depression, but experts ... - CNN
Apr 2, 2024 · The US Food and Drug Administration is allowing the use of Rejoyn, the first prescription digital treatment for major depressive disorder.
Depression Medications (Antidepressants) - WebMD
Jun 16, 2024 · Depression medications work well for treating moderate, severe, or chronic depression. With so many FDA-approved options, you can work with your doctor to choose the right one based on your ...
The FDA has approved the first app to help treat depression
Apr 4, 2024 · The Food and Drug Administration has approved the first digital tool to help treat major depression. It's an app called Rejoyn, and it's only available through a prescription.
A Comprehensive Review of Novel FDA-Approved Psychiatric …
We searched and reviewed novel psychiatric medications approved by the FDA from 2018 to 2022. We then analyzed each medication in the United States Clinical Trials Registry and gathered updated results for efficacy and safety information.
FDA approves first prescription digital therapy for major depression
Apr 5, 2024 · The U.S. Food and Drug Administration (FDA) has cleared the first prescription digital therapeutic authorized for the adjunctive treatment of major depressive disorder (MDD) symptoms.
SPRAVATO® (esketamine) approved in the U.S. as the first and …
Jan 21, 2025 · SPRAVATO ® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO® alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms compared to placebo as early as 24 hours1 SPRAVATO® alone showed a rapid ...
FDA approves standalone use of J&J’s ketamine-derived depression ...
Jan 22, 2025 · The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the ...
- Some results have been removed